Literature DB >> 16331671

Automated sequence screening of the entire dystrophin cDNA in Duchenne dystrophy: point mutation detection.

Sherifa Ahmed Hamed1, Eric P Hoffman.   

Abstract

This is the first report of direct sequencing of the complete 11 kb coding sequence of the dystrophin gene affording high sensitivity for all types of mutations of both coding sequence and splicing. Direct automated capillary gel sequence analysis of dystrophin reverse-transcribed polymerase chain reaction (RT-PCR) products was carried out in 15 Duchenne muscular dystrophy (DMD) patient muscle biopsies (170,000 bp sequenced). We identified mutations in 67% of patients tested (10/15); including premature stop codons (n = 5) and small deletions/duplications (n = 5). Mutation-negative patients (n = 5) were also negative for promoter mutations. All were tested for the possibility of transcription abnormalities using quantitative multiplex fluorescence polymerase chain studies (QMF-PCR), however, equal ratios of mRNA transcripts were identified at the 5'and 3' regions, with mild reduction in overall quantity, suggesting that transcription abnormalities were less likely. We suggested that such patients might have a problem with the 3.5 kb 3' UTR, polyA site or undetected stop codons. It is also possible that splicing defects could result in addition of intron sequence which could lead to preferential amplification of low level residual normal transcript skipping. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331671     DOI: 10.1002/ajmg.b.30234

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  8 in total

1.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

2.  Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.

Authors:  Nikolaos Vogiatzakis; Kyriaki Kekou; Christalena Sophocleous; Sophia Kitsiou; Ariadni Mavrou; Chrisa Bakoula; Emmanouel Kanavakis
Journal:  Mol Biotechnol       Date:  2007-08-03       Impact factor: 2.695

3.  Internal deletion compromises the stability of dystrophin.

Authors:  Davin M Henderson; Joseph J Belanto; Bin Li; Hanke Heun-Johnson; James M Ervasti
Journal:  Hum Mol Genet       Date:  2011-05-10       Impact factor: 6.150

4.  Whole dystrophin gene analysis by next-generation sequencing: a comprehensive genetic diagnosis of Duchenne and Becker muscular dystrophy.

Authors:  Yan Wang; Yao Yang; Jing Liu; Xiao-Chun Chen; Xin Liu; Chun-Zhi Wang; Xi-Yu He
Journal:  Mol Genet Genomics       Date:  2014-04-27       Impact factor: 3.291

5.  Microarray-based mutation detection in the dystrophin gene.

Authors:  Madhuri R Hegde; Ephrem L H Chin; Jennifer G Mulle; David T Okou; Stephen T Warren; Michael E Zwick
Journal:  Hum Mutat       Date:  2008-09       Impact factor: 4.878

6.  Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.

Authors:  Nikolaos Vogiatzakis; Kyriaki Kekou; Christalena Sophocleous; Sophia Kitsiou; Ariadni Mavrou; Chrisa Bakoula; Emmanouel Kanavakis
Journal:  Mol Biotechnol       Date:  2007-08-14       Impact factor: 2.695

7.  DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations.

Authors:  Jonas Juan-Mateu; Lidia Gonzalez-Quereda; Maria Jose Rodriguez; Manel Baena; Edgard Verdura; Andres Nascimento; Carlos Ortez; Montserrat Baiget; Pia Gallano
Journal:  PLoS One       Date:  2015-08-18       Impact factor: 3.240

8.  Prenatal diagnosis of Duchenne muscular dystrophy revealed a novel mosaic mutation in Dystrophin gene: a case report.

Authors:  Yan Wang; Yuhan Chen; San Mei Wang; Xin Liu; Ya Nan Gu; Zhichun Feng
Journal:  BMC Med Genet       Date:  2020-11-11       Impact factor: 2.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.